These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37651467)

  • 1. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Aljasser A; Colon-Ascanio M; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais PR; Tan H; Wang J; Chen Y; Choy JS
    PLoS Pathog; 2023 Aug; 19(8):e1011592. PubMed ID: 37651467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    Res Sq; 2022 Aug; ():. PubMed ID: 36052369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A yeast-based system to study SARS-CoV-2 M
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
    Costacurta F; Dodaro A; Bante D; Schöppe H; Peng JY; Sprenger B; He X; Moghadasi SA; Egger LM; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Dunzendorfer-Matt T; Naschberger A; Wang D; Kaserer T; Moro S; von Laer D; Heilmann E
    PLoS Pathog; 2024 Sep; 20(9):e1012522. PubMed ID: 39259728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V.
    Xia YL; Du WW; Li YP; Tao Y; Zhang ZB; Liu SM; Fu YX; Zhang KQ; Liu SQ
    J Chem Inf Model; 2024 Jul; 64(13):5207-5218. PubMed ID: 38913174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense.
    Ju X; Wang Z; Wang P; Ren W; Yu Y; Yu Y; Yuan B; Song J; Zhang X; Zhang Y; Xu C; Tian B; Shi Y; Zhang R; Ding Q
    mBio; 2023 Aug; 14(4):e0137323. PubMed ID: 37439567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses.
    Chakraborty C; Bhattacharya M; Alshammari A; Alharbi M; Albekairi TH; Zheng C
    J Infect Public Health; 2023 Dec; 16(12):1961-1970. PubMed ID: 37883855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
    Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
    Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021-September 2023.
    Duvvuri V; Shire F; Isabel S; Braukmann T; Clark S; Marchand-Austin A; Eshaghi A; Bandukwala H; Varghese N; Li Y; Sivaraman K; Hussain H; Cronin K; Sullivan A; Li A; Zygmunt A; Ramotar K; Kus J; Hasso M; Corbeil A; Gubbay J; Patel S
    Can Commun Dis Rep; 2024 Oct; 50(10):365-374. PubMed ID: 39386278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA.
    Arif MN
    Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir.
    Paciaroni A; Libera V; Ripanti F; Orecchini A; Petrillo C; Francisci D; Schiaroli E; Sabbatini S; Gidari A; Bianconi E; Macchiarulo A; Hussain R; Silvestrini L; Moretti P; Belhaj N; Vercelli M; Roque Y; Mariani P; Comez L; Spinozzi F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
    Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.